HKUMed research team identifies new drug combo for liver cancer via CRISPR-Cas9 screen

19 Dec 2021

A research team of LKS Faculty of Medicine, The University of Hong Kong (HKUMed) has successfully repurposed an approved drug ifenprodil, a vasodilator, to be used in combination with the FDA-approved first-line drug sorafenib for hepatocellular carcinoma (HCC) treatment. This study leveraged on their CombiGEM-CRISPR v2.0 screening platform1 to expedite the search among the many possible drug combinations to inhibit druggable targets in the genome for treating HCC. The findings are now published in Cancer Research.
[Publication: https://aacrjournals.org/cancerres/article-abstract/81/24/6219/674810/A-Combinatorial-CRISPR-Cas9-Screen-Identifies?redirectedFrom=fulltext]

This research was led by Dr. Alan Wong Siu-lun, Assistant Professor of the School of Biomedical Sciences, HKUMed, Principal Investigator of the Centre for Oncology and Immunology Limited, and Dr. Stephanie Ma, Associate Professor of the School of Biomedical Sciences, HKUMed, as co-corresponding authors.